Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fer3-like basic helix-loop-helix transcription factor (FERD3L) is a protein-coding gene encoding a transcription factor that functions as an inhibitor of transcription by binding to E-box sequences in DNA, requiring dimerization with an E protein for DNA binding. FERD3L acts as a negative regulator of transcription, notably inhibiting activation by ASCL1/MASH1 through sequestration of E proteins. The gene is involved in several developmental processes, especially within the nervous system, and plays a regulatory role in neurodevelopment and neuronal differentiation[1][2][3][10]. Diseases associated with FERD3L include female stress incontinence and Saethre-Chotzen syndrome, though there is currently no evidence that FERD3L is a direct therapeutic target nor that it interacts with approved drugs[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fer3-like basic helix-loop-helix transcription factor (FERD3L).